Abstract
Gefitinib is an orally active inhibitor of the epidermal growth factor receptor approved for use in patients with locally advanced or metastatic non–small cell lung cancer. It has also been evaluated in several clinical trials for treatment of brain tumors such as high-grade glioma. In this study, we investigated the influence of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) on distribution of gefitinib to the central nervous system. In vitro studies conducted in Madin-Darby canine kidney II cells indicate that both P-gp and BCRP effectively transport gefitinib, limiting its intracellular accumulation. In vivo studies demonstrated that transport of gefitinib across the blood-brain barrier (BBB) is significantly limited. Steady-state brain-to-plasma (B/P) concentration ratios were 70-fold higher in the Mdr1a/b(−/−) Bcrp1(−/−) mice (ratio of approximately 7) compared with wild-type mice (ratio of approximately 0.1). The B/P ratio after oral administration increased significantly when gefitinib was coadministered with the dual P-gp and BCRP inhibitor elacridar. We investigated the integrity of tight junctions in the Mdr1a/b(−/−) Bcrp1(−/−) mice and found no difference in the brain inulin and sucrose space between the wild-type and Mdr1a/b(−/−) Bcrp1(−/−) mice. This suggested that the dramatic enhancement in the brain distribution of gefitinib is not due to a leakier BBB in these mice. These results show that brain distribution of gefitinib is restricted due to active efflux by P-gp and BCRP. This finding is of clinical significance for therapy in brain tumors such as glioma, where concurrent administration of a dual inhibitor such as elacridar can increase delivery and thus enhance efficacy of gefitinib.
Footnotes
This work was supported in part by National Institutes of Health National Cancer Institute [Grant CA138437] (to W.F.E. and J.R.O.) and the Children's Cancer Research Fund at the University of Minnesota (to W.F.E, J.R.O). Financial support for S.A. was provided by the Edward G. Rippie Fellowship and the Ronald J. Sawchuk Fellowship in Pharmacokinetics from the Department of Pharmaceutics, University of Minnesota.
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
doi:10.1124/jpet.110.167601.
-
ABBREVIATIONS:
- CNS
- central nervous system
- BBB
- blood-brain-barrier
- MDR1
- multi-drug resistance protein 1
- P-gp
- P-glycoprotein
- BCRP
- breast cancer resistance protein
- A-to-B
- apical-to-basolateral
- B-to-A
- basolateral-to-apical
- Peff
- effective permeability
- B/P
- brain-to-plasma
- ER
- efflux ratio
- GBM
- glioblastoma multiforme
- EGFR
- epidermal growth factor receptor
- EGFRvIII
- epidermal growth factor receptor mutant vIII
- Mdr1
- gene encoding the murine P-glycoprotein
- MDR1
- gene encoding the human P-glycoprotein
- Bcrp1
- gene encoding the murine breast cancer resistance protein
- MS
- mass spectrometry
- ZD1839
- gefitinib
- ABC
- ATP-binding cassette
- GF120918 (elacridar)
- N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide]
- MDCKII
- Madin-Darby canine kidney II
- LY335979 (zosuquidar)
- (R)-4-((1aR,6R,10bS)-1,2-difluoro-1,1a,6,10b-tetrahydrodibenzo-(a,e)cyclopropa(c)cycloheptan-6-yl)-α-((5-quinoloyloxy) methyl)-1-piperazine ethanol, trihydrochloride
- Ko143
- (3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino(1',2':1,6) pyrido(3,4-b)indole-3-propanoic acid 1,1-dimethylethyl ester
- WT
- wild type
- DMSO
- dimethyl sulfoxide
- FVB
- Friend Leukemia Virus Strain B.
- Received February 23, 2010.
- Accepted April 23, 2010.
- Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|